KFDA announces Novartis Korea's verteporphin as first bulk drug at eligible foreign plant

Published: 2003-05-01 06:56:00

Updated: 2003-05-01 06:56:00

The Korea Food and Drug Administration notified via Internet on April 28 that Novartis Korea's verteporphin (drug for the treatment of age-related macular degeneration) is the first pharmaceutical bulk material produced at an eligible manufacturing presence since the implementation of the current...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK